Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Treasury Shares (2016 - 2026)

Amphastar Pharmaceuticals has reported Treasury Shares over the past 12 years, most recently at $408.1 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 22.67% year-over-year to $408.1 million; the TTM value through Dec 2025 reached $408.1 million, up 22.67%, while the annual FY2025 figure was $408.1 million, 22.67% up from the prior year.
  • Treasury Shares for Q4 2025 was $2.9 million at Amphastar Pharmaceuticals, up from $172920.0 in the prior quarter.
  • Over five years, Treasury Shares peaked at $2.9 million in Q4 2025 and troughed at -$15.2 million in Q2 2025.
  • A 5-year average of -$3.6 million and a median of $181380.0 in 2022 define the central range for Treasury Shares.
  • Biggest five-year swings in Treasury Shares: increased 15.72% in 2021 and later skyrocketed 49.67% in 2025.
  • Year by year, Treasury Shares stood at $150.5 million in 2021, then grew by 25.95% to $189.5 million in 2022, then soared by 30.55% to $247.4 million in 2023, then soared by 34.47% to $332.7 million in 2024, then grew by 22.67% to $408.1 million in 2025.
  • Business Quant data shows Treasury Shares for AMPH at $408.1 million in Q4 2025, $387.7 million in Q3 2025, and $382.8 million in Q2 2025.